What it is
MGM-15 is a semi-synthetic opioid made by chemically reducing 7-OH. Structurally, it’s the 1,2-dihydro version of 7-OH. In academic papers it’s sometimes also written as “DiHydro-7-OH-Mitragynine” or “DH-7OH-MIT” — not the same molecule as dihydromitragynine (DHM) sold under “MIT-A”.
Where it came from
First reported by Japanese researchers in 2014 as a candidate analgesic. It sat in the academic literature for about a decade before showing up in U.S. designer-drug products in early 2025. Its 9-fluoro analog, MGM-16, is roughly 240× the potency of morphine in animal studies — same scaffold with a fluorine added.
Pharmacology
A high-affinity full agonist at both the mu-opioid receptor (~28 nM at hMOR) and the delta-opioid receptor (~59 nM at hDOR), exceeding 7-OH at both. The dual MOR/DOR action matters — it’s a big part of why this compound behaves differently from medications that only hit mu, and why switching off it onto something MOR-only doesn’t feel like a clean swap.
Half-life — this is the part most people underestimate
MGM-15 has a half-life of around 15 hours. For comparison, 7-OH is short-acting (typically a few hours, which is why people redose so often).
- After ~15 hours, roughly half is still on your receptors. After 24 hours, about a third. Full elimination takes ~3–4 days.
- Withdrawal onset is delayed compared to 7-OH — you may not feel it for 24–48+ hours after the last dose, and once it hits, it lasts longer.
- Dose-stacking sneaks up on people. If you’re redosing on the same schedule that worked for 7-OH, MGM-15 accumulates well past where you think you are.
Why Suboxone is tricky with MGM-15 — and why bupe may not “take the edge off”
Two separate issues. Both pharmacological, both worth understanding before you try this transition:
1. Precipitated withdrawal risk is bigger and lasts longer than the standard guidance assumes. Typical Suboxone induction guidance is to wait 12–24 hours after the last opioid dose. That window was built around shorter-acting opioids and works fine for 7-OH. With MGM-15’s ~15-hour half-life, that window is often not enough — there’s still meaningful MGM-15 sitting on your receptors. Buprenorphine has extremely high MOR affinity and will displace it, but bupe is only a partial agonist, so the swap drops receptor activation hard and fast → precipitated withdrawal. There are reports of attempted micro-inductions where every time the dose reached 1–2 mg, precipitated withdrawal set in, making the process intolerable.
2. Even after a clean induction, bupe may not fully cover symptoms — and this isn’t your imagination.
- Buprenorphine has a ceiling effect (partial agonist), so its maximum MOR activation is lower than what a full agonist like MGM-15 was delivering. You’re stepping down receptor activation, not replacing it 1:1.
- MGM-15 activates both mu and delta receptors. Buprenorphine essentially only hits mu (and is actually an antagonist at delta). The delta contribution to mood, analgesia, and overall opioid tone that MGM-15 was providing — bupe doesn’t replace it at all. 7-OH is mu-dominant, so this gap shows up much harder coming off MGM-15 than coming off 7-OH.
- Net effect: people coming off MGM-15 onto Suboxone often report bupe doesn’t fully cover them, especially restlessness, low mood, anhedonia, and a persistent low-grade “off” feeling. Stabilization typically takes 2–3 weeks, and many people need a higher stabilizing dose than their initial induction dose to fully settle.
What people have found helps: a longer washout than the standard 12–24 hours when feasible (closer to 36–72 hours puts you well past the worst of MGM-15’s receptor occupancy), a prescriber who actually understands kratom-derivative dependence, and being upfront about the dual-receptor pharmacology so a higher stabilizing dose is on the table from day one. Share what’s worked or not worked here — community knowledge on this is genuinely ahead of the published literature.
General risks
- Tolerance and dependence develop fast.
- Withdrawal resembles classical opioid withdrawal, often more intense and longer than 7-OH withdrawal because of the half-life and full-agonist profile.
- Respiratory depression risk, especially mixed with benzos, alcohol, gabapentinoids, or other opioids.
- Naloxone (Narcan) reverses overdose.
- Products sold as “MGM-15” may contain 7-OH or other unlabeled mitragynine derivatives.
Legal status
Already named in Ohio’s scheduling action alongside 7-OH, MP, and 7-acetoxymitragynine. The FDA recommended scheduling 7-OH in July 2025; MGM-15 will likely fall under analog enforcement if 7-OH gets scheduled federally.